Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

Key findings

Published obesity trials used once-weekly subcutaneous injection.
Retatrutide has no approved consumer device or prescribing schedule.
Trial participants should follow the supplied product’s training, storage and missed-dose instructions.
Another medicine’s pen instructions do not validate an unknown retatrutide product.

How to Inject Retatrutide

Retatrutide’s published obesity trials use once-weekly subcutaneous injection, meaning injection into the tissue beneath the skin. It remains investigational, so there is no FDA-approved retatrutide pen, preparation guide or prescribing schedule for routine use.

If you are a trial participant, your study team’s instructions are the authority for your supplied product. Instructions for Mounjaro, Zepbound or Wegovy cannot be assumed to apply to retatrutide. A vial sold online as “retatrutide” or “GLP-3” is not verified clinical-trial supply.

Injection Basics

Question	What is established
How was it given in published obesity trials?	Once weekly by subcutaneous injection.
Is there an approved retail device?	No. A future commercial device and instructions have not been established by an approved label.
Does it need reconstitution?	That cannot be answered for an unknown product. Trial participants must follow their supplied formulation’s instructions.
Is there a standard prescribed dose?	No approved prescribing schedule exists. Trial regimens differ.

Injection Sites

Ask the study team to show the permitted sites for the supplied product and demonstrate the technique. Do not transfer needle, depth, angle or device instructions from another medicine: the same subcutaneous route does not mean every device works the same way.

Site Rotation

Follow the study’s instructions for changing sites and report redness, swelling, pain or other local symptoms. This review does not establish a retatrutide-specific spacing rule or guarantee that rotating sites prevents a reaction.

Dose Titration Schedule

Trials escalated doses to evaluate tolerability and efficacy. In the Phase 2 obesity trial, lower starting doses reduced gastrointestinal events. TRIUMPH-4 used 9 mg and 12 mg targets after gradual escalation. Those are study designs, not directions for starting or increasing an unapproved product.

Trial participants should ask the team what to do before the next dose if they have ongoing vomiting, difficulty eating or drinking, or a missed injection. Do not improvise a change from another GLP-1 medicine’s schedule. See trial dosing evidence.

Step-by-Step Injection Process

There is no validated universal step-by-step process for retatrutide. Before a trial injection, have the study team confirm:

The supplied product: its identity, assigned dose and current expiry or use period.
The device: how to prepare it, deliver a complete dose and recognize a device problem.
The technique: permitted sites and whether assistance or supervised practice is needed.
The schedule: what to do after a delayed dose, interrupted treatment or a dose that may not have been delivered.
Aftercare: disposal, symptom reporting and the number to call for advice.

An online video or a concentration calculation cannot verify a powder vial’s contents, sterility or potency. For the evidence gap around powder products, see Retatrutide Reconstitution.

Storage

Storage depends on the actual formulation and container. This review found no approved retatrutide label supporting a general 28-day room-temperature allowance, a travel temperature limit or a recommended warming period before injection.

Use the written instructions supplied by the trial. If the product has been outside those conditions, damaged or left in uncertain storage, contact the study team before using it. Appearance alone cannot establish potency or sterility.

Gastrointestinal (Most Common)

The Phase 2 obesity trial’s common adverse events included nausea, diarrhea, vomiting and constipation. They were dose-related, mostly mild or moderate, and often occurred during escalation. These are effects of treatment, not necessarily evidence that the injection technique was wrong. There is no universal deadline by which they must resolve.

For the full trial findings and symptom guidance, see Retatrutide Side Effects.

Injection Site Reactions

Tell the study team about local symptoms, especially worsening pain, spreading redness, swelling or a persistent reaction. Do not assume an online remedy or a change in injection technique will address the cause. Trial safety data also describe altered skin sensation that is distinct from a reaction at the injection site.

How Retatrutide Injection Compares

Feature	Retatrutide	Approved tirzepatide or semaglutide injections
Route	Subcutaneous in published obesity trials	Subcutaneous, according to the individual product label
Instructions	Study-specific	Product- and device-specific approved instructions
Missed dose	Contact the study team	Follow that medicine’s current label
Device and storage	Do not assume a future commercial presentation	Can vary by brand, presentation and country

Sharing a manufacturer or route does not establish an identical pen, priming process, storage period or missed-dose window.

Frequently Asked Questions

Is retatrutide a pill or injection?

The published obesity program studies a once-weekly subcutaneous injection. There is no approved oral retatrutide product. See oral versus injection options.

How often do you inject retatrutide?

Published obesity trials used once-weekly administration. A trial participant’s timing, delayed-dose and restart instructions must come from the study team; twice-weekly splitting is not established by these results.

Does the injection hurt?

Discomfort depends on the device, technique and individual. There is no approved retatrutide needle specification or warming instruction to apply universally. Ask the study team to demonstrate the supplied device and report persistent pain or reactions.

Can I inject retatrutide myself?

Trial participants should follow the training and supervision requirements of their study. The fact that some approved GLP-1 pens permit self-administration does not validate an unknown retatrutide product or device.

What happens if I miss a dose?

Contact the study team for the protocol that applies to your assigned treatment. Do not borrow a catch-up window from semaglutide or tirzepatide, double a dose or guess how to restart after an interruption.

Can you inject retatrutide into a vein or muscle?

Those routes are not the route used in the published obesity trials, which used subcutaneous injection. Do not improvise a different route. If an injection may have gone wrong, contact the study team promptly instead of repeating the dose to compensate.

Sources

Jastreboff, A.M., et al. (2023). Retatrutide Phase 2 obesity trial. New England Journal of Medicine.
Lilly. (2025). TRIUMPH-4 trial results and escalation protocol.
FDA. Concerns with unapproved GLP-1 drugs.
Novo Nordisk. Wegovy prescribing information.
FDA. Zepbound prescribing information.

Questions to ask your doctor

Given my health history, is a GLP-1 medication appropriate for me at all?
Which approved option (e.g. semaglutide, tirzepatide) best fits my goals?
What starting dose and titration pace would you use, and why?
What side effects should I watch for, and when should I call you?
How will we monitor whether it's working and when to adjust?

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources

Phase 2 trial (NEJM)
NEJM
Find retatrutide trials
ClinicalTrials.gov

Grounded in primary sources

NEJM

The Lancet

JAMA

FDA

ClinicalTrials.gov

How to Inject Retatrutide

Injection Basics